Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion

Wang, Hongmin; Cui, Yuzhong; Wang, Sheng; Zhao, Rusen; Sun, Ming

doi:10.12659/msm.897657

Cited by 4 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trials of combined therapies showed that combination of autologous DC and cytokine-induced killer (CIK) cells to treat effusions had comparably mild side effects but only modest efficacy. 178 An anecdotal report of intrapleural administration of tumor infiltrating lymphocyte (TIL) infusion compared to traditional cisplatin therapy demonstrated a claimed but very modest greater response rate (33.3% vs 28.57%) and disease control (71.43% vs 66.67%) than MPE patients given cisplatin. 183 Certainly, local and systemic TIL therapy is an area worthy of further consideration.…”

Section: Interferon Therapymentioning

confidence: 99%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusions, arising from either primary mesotheliomas or secondary malignancies, heralds advanced disease and poor prognosis. Current treatments, including therapeutic thoracentesis and tube thoracostomy, are largely palliative. The immunosuppressive environment within the pleural cavity includes myeloid derived suppressor cells, T-regulatory cells, and dysfunctional T cells. The advent of effective immunotherapy with checkpoint inhibitors and adoptive cell therapies for lung cancer and other malignancies suggests a renewed examination of local and systemic therapies for this malady. Prior strategies reporting remarkable success, including instillation of the cytokine interleukin-2, perhaps coupled with checkpoint inhibitors, should be further evaluated in the modern era.

show abstract

Section: Interferon Therapymentioning

confidence: 99%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Clinical studies paid more attention to the patients’ quality of life after treatment. Ten studies calculated the Karnofsky score (KPS) to quantify patients' general well‐being and quality of life and 8 of them indicated higher KPS after CIK cell therapy (N. Li et al, 2019; H. Luo et al, 2016; Y. Liu et al, 2016; Lu et al, 2012; Qiu et al, 2011; H. Wang, Cui, Wang, Zhao, & Sun, 2016; Yan et al, 2015; Yu et al, 2011). Patients in other studies also achieved an improvement of the general condition in different degrees including better appetite, improved sleep, weight gain, pain relief, and so forth.…”

Section: Resultsmentioning

confidence: 99%

“…The mOS of patients that received autologous CIK cell immunotherapy was significantly prolonged by 8 months with a significantly increased 3‐year OS rate (D. Chen, Sha, et al, 2018). A study on 82 patients with advanced pancreatic cancer demonstrated significantly increased mOS, disease control rate, and 6‐, 12‐, 18‐month OS rate (Z. Wang, Liu, et al, 2016). Another study including 646 postoperative epithelial ovarian cancer patients showed a significantly higher OS rate and a favorable PFS in the CIK cell plus chemotherapy group (Y. Zhou, Chen, et al, 2019).…”

Section: Resultsmentioning

confidence: 99%

“…Clinical studies paid more attention to the patients' quality of life after treatment. Ten studies calculated the Karnofsky score (KPS) to quantify patients' general well-being and quality of life and 8 of them indicated higher KPS after CIK cell therapy (N. Li et al, 2019;Lu et al, 2012;Qiu et al, 2011;H. Wang, Cui, Wang, Zhao, & Sun, 2016;Yan et al, 2015;Yu et al, 2011).…”

Section: Clinical Outcome Therapeutic Regime and Quality Of Lifementioning

confidence: 99%

See 1 more Smart Citation

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Zhang

Schmidt‐Wolf

2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Cytokine‐induced killer (CIK) cells represent an exceptional T‐cell population uniting a T cell and natural killer cell‐like phenotype in their terminally differentiated CD3+CD56+ subset, which features non‐MHC‐restricted tumor‐killing activity. CIK cells have provided encouraging results in initial clinical studies and revealed synergistic antitumor effects when combined with standard therapeutic procedures. We established the international registry on CIK cells (IRCC) to collect and evaluate clinical trials for the treatment of cancer patients in 2010. Moreover, our registry set new standards on the reporting of results from clinical trials using CIK cells. In the present update, a total of 106 clinical trials including 10,225 patients were enrolled in IRCC, of which 4,889 patients in over 30 distinct tumor entities were treated with CIK cells alone or in combination with conventional or novel therapies. Significantly improved median progression‐free survival and overall survival were shown in 27 trials, and 9 trials reported a significantly increased 5‐year survival rate. Mild adverse effects and graft‐versus‐host diseases were also observed in the studies. Recently, more efforts have been put into the improvement of antitumoral efficacy by CIK cells including the administration of immune checkpoint inhibitors and modification with chimeric antigen receptorc. The minimal toxicity and multiple improvements on their tumor‐killing activity both make CIK cells a favorable therapeutic tool in the clinical practice of cancer immunotherapy.

show abstract

“…95 Other clinical trials have demonstrated that the use of CIK therapy prolongs median overall survival and has a favorable effect on progression-free survival in colon, lung, pancreatic, and ovarian cancers. [96][97][98][99] These trials demonstrate the utility of CIK cells as a form of immunotherapy while also raising questions regarding the optimal length of maintenance treatments and frequency of CIK infusions. Further studies will be needed to compare efficacy between autologous and allogeneic CIK cells.…”

Section: Cytokine-induced Killer Cells In Immunotherapymentioning

confidence: 99%

The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies

et al. 2023

View full text Add to dashboard Cite

Introduction: Immunotherapy has revolutionized how cancer is treated. Many of these immunotherapies rely on ex vivo expansion of immune cells, classically T cells. Still, several immunological obstacles remain, including tumor impermeability by immune cells and the immunosuppressive nature of the tumor microenvironment (TME). Logistically, high costs of treatment and variable clinical responses have also plagued traditional T cell-based immunotherapies. Methods: To review the existing literature on cellular immunotherapy, the PubMed database was searched for publications using variations of the phrases "cancer immunotherapy", "ex vivo expansion", and "adoptive cell therapy". The Clinicaltrials.gov database was searched for clinical trials related to ex vivo cellular therapies using the same phrases. The National Comprehensive Cancer Network guidelines for cancer treatment were also referenced. Results: To circumvent the challenges of traditional T cell-based immunotherapies, researchers have developed newer therapies including tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR), T cell receptor (TCR) modified T cell, and antibody-armed T cell therapies. Additionally, newer immunotherapeutic strategies have used other immune cells, including natural killer (NK) and dendritic cells (DC), to modulate the T cell immune response to cancers. From a prognostic perspective, circulating tumor cells (CTC) have been used to predict cancer morbidity and mortality. Conclusion: This review highlights the mechanism and clinical utility of various types of ex vivo cellular therapies in the treatment of cancer. Comparing these therapies or using them in combination may lead to more individualized and less toxic chemotherapeutics.

show abstract

Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion

Cited by 4 publications

References 13 publications

Making cold malignant pleural effusions hot: driving novel immunotherapies

Making cold malignant pleural effusions hot: driving novel immunotherapies

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies

Contact Info

Product

Resources

About